Cystic Fibrosis Can Lead to Other Conditions

cystic fibrosisIf you suffer from Cystic Fibrosis, then you already know the struggles associated with having the disease, but can CF lead to more? Recent studies have shown that it might. In a study published in the Cystic Fibrosis Journal, researchers were eager to determine the effects of Cystic Fibrosis and how the disease could trigger other illnesses, and the study titled “The risk of asthma in heterozygous carriers for cystic fibrosis: A meta-analysis,” did just that. The researchers based their groundwork on previous studies that reported a clear association between CF heterozygous carriers and the chance of an elevated risk of asthma. A heterozygous carrier is someone who only has one of the CFTR (Cystic Fibrosis Transmembrane conductance Regulator) genes, which means that they don’t actively have Cystic Fibrosis, but they are still likely to pass the illness onto future generations. The analysis consisted of 15 studies that involved 2,113 asthma cases and 13,457 controls. A meta-analysis was performed on published literature obtained between the years of 1966 and 2015. After all the legwork had been completed, the results were clear: CF heterozygous individuals may indeed carry a higher risk of asthma development. On top of that, it was found that the risk of these individuals obtaining asthma was even higher in Asian countries. This leads them to believe that those with Cystic Fibrosis were more affected by the environmental, demographic and social factors of Asian countries than European countries. These findings will be documented until the completion of future large cohort studies. The EliTech Group prides itself on being the world leader in Cystic Fibrosis screenings, and our testing strategies help in allowing quicker treating for all newborns that have the disease. Our tools, including the sweat collection system, Neonatal Sweat Analysis System and Chloro-Chek® Chloridometer, are truly marvels of medical technology in testing for Cystic Fibrosis. Contact us here to find out more.”

Latest news


ELITechGroup Announces Regulatory Approval of its Blood Borne Virus Panel in Japan

ELITechGroup’s blood-borne virus (BBV) panel received approval from Japan’s Pharmaceuticals and Medical Devices Agency (PMDA) The ELITe BBV panel was launched in 2022 and comprises three quantitative IVD assays targeting Human Immunodeficiency virus-1 (HIV-1), Human Hepatitis B Virus (HBV), and Human Hepatitis C Virus (HCV) Turin, June 13, 2024: ELITechGroup…

ELITechGroup achieves a new CE-IVDR Certification

ELITechGroup continues to expand its portfolio of IVDR-certified PCR assays to support European diagnostic laboratories The newly obtained IVDR certificate will expedite the transition to IVDR for quantitative Class C infectious diseases assays The company is fully committed to delivering its entire portfolio of nearly 60 molecular assays as IVDR…

ELITechGroup Launches Second IVDR Certified Gastrointestinal Infection Assay: GI Parasitic PLUS ELITe MGB® Kit 

ELITechGroup launches their second kit of the Gastrointestinal infection assay panel targeting parasitic pathogens.  The ELITe MGB Gastrointestinal assays are IVDR-certified in combination with InGenius and BeGenius, fully automated samples-to-results instruments.  The company will shortly launch two more gastrointestinal assay infection panels targeting viral pathogens and Norovirus.   ELITechGroup announces the…

Let us help you

For general inquiries, please use the links to the right. The Contact link leads to a brief online form, and the Support link offers general phone and email information. Someone will be in touch with you soon.